Mariner
LGND icon

Mariner’s Ligand Pharmaceuticals LGND Stock Holding History

Mariner’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,537
Closed -$272K – 3689
2025
Q3 		$272K Buy
+1,537
New +$228K ﹤0.01% 2894
2025
Q1 		– Sell
-2,574
Closed -$276K – 3531
2024
Q4 		$276K Buy
+2,574
New +$291K ﹤0.01% 2704

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Mariner's LGND Position: Q4 2025 in Review

Mariner sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 1,537 shares — an estimated $272K sold.

Mariner first reported a position in LGND in Q4 2024 and held it in 2 quarters. The position peaked at $276K in Q4 2024. 350 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • Mariner reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Mariner sold 1,537 Ligand Pharmaceuticals shares in Q4 2025, an estimated $272K.
  • Mariner first reported a position in Ligand Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Mariner's Ligand Pharmaceuticals position peaked at $276K in Q4 2024.
  • 350 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on Mariner's 13F filing for Q4 2025, filed 13 Feb 2026.